Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Haemorrhagic Stroke Treatment Market: By Drug Type: Antihypertensive, Anticoagulants, Anticonvulsants, Others; By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Others; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Haemorrhagic Stroke Treatment Market Outlook
The global haemorrhagic stroke treatment market is expected to grow at a CAGR of 4.10% during the period 2022-2027. While rates of incidence of haemorrhagic stroke are heterogenous across the globe, Low and Middle Income countries (LMIC) such as those in Asia and Africa have been witnessing an upward trend.
Global Market Likely to be Driven by Cases of Stroke, Especially in Low and Middle Income Countries (LMIC)
While there is significant regional difference in incidence rates of haemorrhagic stroke, highest rates have been observed in LMIC regions such as sub-Saharan Africa and East Asia.
It is estimated that nearly 750,000 strokes take place in the USA every year. During a stroke, one or more regions in the brain may suffer damage, and an individual may experience loss of ability to move to one side of the body depending on the region affected. The damage may be permanent or temporary, and loss of function may be partial or full. Long-term outcome depends on the extent of brain damage, how quickly treatment starts, and several other factors.
Strokes may lead to long-lasting injury, disability, and even death. Early treatment and precautionary measures may decrease brain damage due to stroke. Treatment depends on stroke type (e.g. ischemic or haemorrhagic), the time since the first stroke symptoms appeared, and the individual’s underlying medical issues. Haemorrhage refers to bleeding. Haemorrhagic stroke takes place when blood vessels in the brain rupture or leak, leading to bleeding in or around the brain. It is estimated that nearly twenty percent strokes are haemorrhagic strokes. Damage may quickly occur because of pressure exerted by increasing amounts of blood or due to the blood itself. Blood irritates the brain tissue, and makes it swell. Bleeding around the brain is called subarachnoid haemorrhage (SAH), and is generally caused when an anomalous blood vessel (aneurysm) on the brain’s surface ruptures. Bleeding into the brain is known as intracerebral haemorrhage (ICH), and is generally caused by high blood pressure.
Treatments Options for Haemorrhagic Stroke Expected to Drive the Global Haemorrhagic Stroke Treatment Market
Treatment of haemorrhagic stroke depends on the cause of bleeding (e.g. anticoagulant medications, high blood pressure, trauma to the head, blood vessel malformation). Most patients need to be closely monitored in an ICU during and after a haemorrhagic stroke. Care for an individual suffering from haemorrhagic stroke includes identifying the cause of bleeding; regulating blood pressure; and stopping medication that could aggravate bleeding. A ventriculostomy tube is placed in the ventricle to measure pressure in the brain. If the pressure is high, some cerebrospinal fluid may be removed from the ventricle. A ventriculostomy may be employed to drain blood that has accumulated in the brain due to the stroke.
Treatments for haemorrhagic stroke include:
Surgical treatment — Surgery may be carried out to prevent or stop bleeding, or decrease pressure inside the skull. According to severity of stroke and the patient's condition, surgery may be performed within the first forty-eight to seventy-two hours after the haemorrhage; however, it may also be postponed to be done one to two weeks later to let the patient's condition stabilize.
Aneurysm treatment — An aneurysm refers to a blood vessel with a weak spot that protrudes out. If the area ruptures and bleeds, a haemorrhagic stroke could occur.
A clamp could be placed at the aneurysm’s base to prevent bleeding before a stroke or to stop rebleeding. The procedure entails removing a piece of the skull and tracing the aneurysm within the brain tissue; general anesthesia is generally employed and the procedure takes several hours. The piece of skull is replaced after the procedure.
Coil embolization is a procedure less invasive than clipping; it may be performed while the patient is sedated or put to sleep with the help of medicines. A flexible tube (catheter) is inserted into an artery in the groin, guided along blood vessels in the body into the brain vessel with the aneurysm. A minute coil is guided into aneurysm, filling the area with the coil. A blood clot is created within the coil, which blocks blood flow into the aneurysm and prevents it from rupturing again. Other materials may be injected to treat an aneurysm or arteriovenous malformation (AVM). New treatment systems employ stents (flow diverters) that reduce blood flow to the aneurysm.
Arteriovenous malformation treatment — Some AVMs carry a substantial risk of further bleeding. The decision to treat an AVM may depend on many factors, key factors being patient age, AVM location and size, vein abnormalities that drain the malformation, and whether the AVM has bled previously. Treatment could include surgery, radiosurgery, or embolization techniques.
Decompressive craniotomy — This procedure may be decided upon in cases where a patient's life seems threatened by pressure effects of a blood clot in the brain; it entails opening the skull and/or removing the blood. Considerations include size and location of haemorrhage, age and medical condition of patient, and the chances of recovery from the stroke.
Global Haemorrhagic Stroke Treatment Market Likely to be Driven by Demand for Medicines Used in Treatment
Medications for haemorrhagic stroke include:
- Beta Blockers, Alpha Activity.
- Vasodilators.
- Anticonvulsants, Other.
- Anticonvulsants, Hydantoins.
- Beta Blockers, Beta-1 Selective.
- Calcium Channel Blockers.
- Angiotensin Receptor Blockers.
- Angiotensin-converting Enzyme Inhibitors.
Market Segmentation
By type, the market is segmented into:
- Antihypertensive
- Anticoagulants
- Anticonvulsants
- Others
By distribution channel, the market is divided into:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By region, the market is classified into:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Key Industry Players in the Global Haemorrhagic Stroke Treatment Market
The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- B. Braun Melsungen AG
- Medtronic
- Bayer AG
- Novartis AG
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Haemorrhagic Stroke Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Haemorrhagic Stroke Treatment Historical Market (2017-2021)
8.3 Global Haemorrhagic Stroke Treatment Market Forecast (2022-2027)
8.4 Global Haemorrhagic Stroke Treatment Market by Drug Type
8.4.1 Antihypertensive
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Anticoagulants
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Anticonvulsants
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Others
8.5 Global Haemorrhagic Stroke Treatment Market by Distribution Channel
8.5.1 Hospitals Pharmacies
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Retail Pharmacies
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Online Pharmacies
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.6 Global Haemorrhagic Stroke Treatment Market by Region
8.6.1 Market Share
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 B. Braun Melsungen AG
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Medtronic
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Bayer AG
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Novartis AG
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Pfizer Inc.
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Merck & Co., Inc.
11.2.6.1 Company Overview
11.2.6.2 Product Portfolio
11.2.6.3 Demographic Reach and Achievements
11.2.6.4 Certifications
11.2.7 GlaxoSmithKline plc
11.2.7.1 Company Overview
11.2.7.2 Product Portfolio
11.2.7.3 Demographic Reach and Achievements
11.2.7.4 Certifications
11.2.8 Others
12 Industry Events and Developments
List of Figures and Tables
1. Global Haemorrhagic Stroke Treatment Market: Key Industry Highlights, 2017 and 2027
2. Global Haemorrhagic Stroke Treatment Historical Market: Breakup by Drug Type (USD Million), 2017-2021
3. Global Haemorrhagic Stroke Treatment Market Forecast: Breakup by Drug Type (USD Million), 2022-2027
4. Global Haemorrhagic Stroke Treatment Historical Market: Breakup by Distribution Channel (USD Million), 2017-2021
5. Global Haemorrhagic Stroke Treatment Market Forecast: Breakup by Distribution Channel (USD Million), 2022-2027
6. Global Haemorrhagic Stroke Treatment Historical Market: Breakup by Region (USD Million), 2017-2021
7. Global Haemorrhagic Stroke Treatment Market Forecast: Breakup by Region (USD Million), 2022-2027
8. North America Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
9. North America Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
10. Europe Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
11. Europe Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Asia Pacific Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
13. Asia Pacific Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Latin America Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
15. Latin America Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Middle East and Africa Haemorrhagic Stroke Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
17. Middle East and Africa Haemorrhagic Stroke Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
18. Global Haemorrhagic Stroke Treatment Market Structure
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global cardiac biomarkers market attained a value of nearly USD 9.4 billion in 2021, driven by the increasing cases of critical heart conditions. Aided by the development of cardiac biomarker test...
The global real time location systems (RTLS) for healthcare market attained a value of more than USD 2024.71 million in 2021, driven by the increasing healthcare expenditure. Aided by the rising inves...
The global AI-based fever detection camera market is being driven by the increasing government spending on public health, rapid development of advanced medical equipment, and growing adoption of the p...
The global tele-ICU market is driven by an increase in the number of trained doctors and health care professionals in developed regions and the growing technological advancements. Aided by the governm...
The global internet of things in healthcare market attained a value of USD 87.9 billion in 2021, driven by the rising healthcare expenditure, growing adoption of smart devices, and the availability of...
NEWSLETTER